Program Plus Tablets-Hyperdrug

Presentation Presentation Round, biconvex tablets with four different colours and imprinted codes. Yellow tablets contain: 23.1 mg lufenuron CGV (side 1) IC (side 2) Red tablets contain: 67.8 mg lufenuron CGV (side 1) FMF (side 2) Grey tablets contain: 204.9 mg lufenuron CGV (side 1) GBG (side 2) White tablets contain: 409.8 mg lufenuron CGV (side 1) DDD (side 2) Uses For the prevention and lasting control of flea infestation and the treatment of flea allergic dermatitis in dogs. Program is effective against the dominant flea species Ctenocephalides felis and C. canis. Program tablets can be administered to all dogs including pregnant bitches and puppies taking solid food. Contra-indications, warnings, etc Contra-indications None. The product is compatible with other flea control products. Warnings Wash hands after use. Any unused product or waste material should be disposed of in accordance with national requirements. Pharmaceutical precautions Keep out of the reach of children. For oral treatment only. For animal treatment only. Store in a dry place. Protect from light. Legal category AVM-GSL (previously POM-V) Packaging Quantities Blister packs of six tablets. Further information Program contains lufenuron, a benzoylurea derivative. After administering Program orally to the dog, the active ingredient is quickly absorbed. Sufficient absorption is only achieved if administered on a full stomach. The low excretion rate assures an effective concentration of the active ingredient in the blood for one month. Fleas take up the active ingredient through the blood and transfer it to their eggs. The formation of larval chitin structures, a process typical to insects, is blocked and the development of their numerous offspring is stopped. A new infestation of the home with fleas is prevented. Fleas picked up by the dog outside the home environment are prevented from causing a new infestation of the home.

Presentation Active ingredients: milbemycin oxime and lufenuron. Coated tablets are available in 4 different sizes: Red outer pack, tablets contain: 2.3mg milbemycin oxime and 46mg lufenuron Green outer pack, tablets contain: 5.75mg milbemycin oxime and 115mg lufenuron Yellow outer pack, tablets contain: 11.5mg milbemycin oxime and 230mg lufenuron White outer pack, tablets contain: 23mg milbemycin oxime and 460mg lufenuron Uses PROGRAM PLUS tablets are indicated for the prevention of fleas (Ct. felis, Ct. canis, preadult stages), and for the concurrent prevention of heartworm disease (elimination of 3rd and 4th larval stages of Dirofilaria immitis) and/or treatment of adult stages of gastrointestinal nematodes such as hookworms (Ancylostoma caninum), roundworms (Toxocara canis) and whipworms (Trichuris vulpis) in dogs

Dosage and administration PROGRAM PLUS tablets are administered at a minimum dose of 0.5 mg milbemycin oxime and 10 mg lufenuron per kg body weight. PROGRAM PLUS tablets are available in four sizes and are given according to the weight of the dog.

For dogs greater than 45 kg, a combination of tablets is given, consistent with the recommended minimum dose. PROGRAM PLUS tablets should be administered in the following situations: Puppies To prevent flea infestations with concurrent heartworm prevention and/or gastrointestinal nematode infection medication should start from 2 weeks of age, or from a minimum weight of 1 kg. Dogs in a non-heartworm region PROGRAM PLUS can be used as part of the seasonal prevention of fleas replacing lufenuron mono (PROGRAM tablets) in cases with diagnosed concurrent gastrointestinal nematode infection. After elimination of the nematode infection confirmed by faecal examination, prevention of fleas should continue with PROGRAM tablets if indicated. In puppies, medication with PROGRAM PLUS is recommended up to one month after weaning. Thereafter, prevention of fleas can be continued with lufenuron mono (PROGRAM). Dogs travelling to a heartworm region: To prevent flea infestations and heartworm disease at the same time, dogs travelling to a heartworm risk region should begin medication within one month after arrival. Treatment should continue monthly, with the last administration given after the dog has left the region. Dogs in a heartworm region: Dogs in a heartworm region:To prevent flea infestations and heartworm disease at the same time, medication should begin within one month after the appearance of mosquitoes, or one month before the appearance of fleas, and continue throughout the risk period with the last dose given within one month after the mosquito and flea season finishes. If dogs have a high level of flea infestation at the start of treatment, it may be necessary to apply a flea adulticide during the first one to two months. It is important to treat all dogs and cats in the household for fleas. Cats in the same household should be treated with PROGRAM oral or injectable suspension. Advice on Correct Administration To ensure adequate drug absorption, PROGRAM PLUS tablets must be administered with food (for example mixed with the daily feed) or placed directly in the mouth after feeding. Treatment with PROGRAM PLUS tablets may begin at any time of the year. In geographic areas where the presence of fleas and mosquitoes (heartworm vector) is seasonal, depending on ambient temperature, treatment should be started one month prior to the appearance of the insects and then repeated monthly throughout the risk period. In environments with year-round flea infestations and concurrent heartworm risk, treatment may be continued throughout the year without interruption. Ideally, tablets are administered on the same day each month. If an interval is greater than 6 weeks, treatment should be resumed immediately and be continued at monthly intervals and, in case of heartworm prevention, a veterinarian should be consulted. PROGRAM PLUS tablets immediately block the reproductive cycle of fleas by inhibiting the development of eggs and larvae. Pre-existing generations (e.g. pupae) present in the environment can, however, continue to develop and emerge for several weeks after the start of treatment.

Contra-indications, warnings, etc In heartworm risk regions, or if it is known that a dog has been travelling to and from heartworm risk regions, before commencing PROGRAM PLUS treatment as with any other heartworm preventive, a veterinary consultation is advised to exclude the presence of any concurrent infestation of Dirofilaria immitis. In the case of a positive diagnosis, adulticidal therapy is indicated before administering PROGRAM PLUS. Pale mucous membranes and increased intestinal peristalsis have been observed in some dogs after treatment. The treatment of dogs with a high number of circulating microfilariae can sometimes lead to the appearance of moderate and transitory hypersensitivity reactions, such as pale mucous membranes, vomiting, laboured breathing, or excessive salivation. These reactions are associated with the release of proteins from dead or dying microfilariae and are not a direct toxic effect of the product. If you notice any other side effects, please inform your veterinary surgeon. Warnings For animal treatment only. To be sold on presentation of a veterinary prescription only. Special Precautions for the Disposal of Unused Veterinary Medicinal Product or Waste Materials Derived from such Veterinary Medicinal Products. Any unused PROGRAM PLUS tablets or waste materials derived from them should be disposed of in accordance with national requirements. Pharmaceutical precautions Keep out of the reach and sight of children. Do not store above 25°C. Keep the blister strips in the outer carton.

Legal category POM-V (previously POM). Packaging Quantities Plastic blister packs each containing 6 tablets. Further information Milbemycin oxime, which belongs to the group of macrocyclic lactones, is active against mites, against larval and adult stages of nematodes as well as against larvae of Dirofilaria immitis. No alteration of reproductive function, neither foetal nor neonatal toxicity has been reported for lufenuron and milbemycin oxime used as a monotherapy in dogs. Marketing authorisation numbers Milbemycin oxime/lufenuron 2.3 mg/46 mg Vm 18352/4000 Milbemycin oxime/lufenuron 5.75 mg/115 mg Vm 18352/4001 Milbemycin oxime/lufenuron 11.5 mg/230 mg Vm 18352/4002 Milbemycin oxime/lufenuron 23 mg/460 mg Vm 18352/4003